An article from

Jonathan Gardner

Senior Reporter

381 articles by Jonathan Gardner

Filter by month:

A play-by-play of the FDA meeting on J&J's one-shot coronavirus vaccine
Feb. 26, 2021
Moderna, Pfizer ready multi-pronged plans for coronavirus variants
Feb. 24, 2021
FDA review supports safety, efficacy of J&J coronavirus vaccine
Feb. 24, 2021
AstraZeneca withdraws immunotherapy in bladder cancer after trial failure
Feb. 22, 2021
Pfizer, BioNTech ask FDA approval to ease temperature requirements for coronavirus shot
Feb. 19, 2021
Novartis expects sales lift from expanded heart drug approval
Feb. 17, 2021
FDA approves Regeneron drug for rare genetic form of high cholesterol
Feb. 12, 2021
AstraZeneca plans for adapting vaccine to coronavirus variants, but offers longer timeline than rivals
Feb. 11, 2021
Small biotech gets big win on treatment for rare swelling disorder
Feb. 9, 2021
As COVID-19 becomes a business, vaccine makers confront thorny pricing questions
Feb. 9, 2021
PTC aims again for FDA review of Duchenne drug despite latest miss
Feb. 5, 2021
GSK expands CureVac vaccine partnership, changing course after setbacks
Feb. 3, 2021
Shifting strategy, Coherus buys rights to experimental cancer drug
Feb. 1, 2021
Novavax vaccine prevents COVID-19 in studies, but less effective against new variants
Jan. 28, 2021
Vaccine makers prepare response as coronavirus mutations raise alarms
Jan. 28, 2021
AstraZeneca, with new data, claims its leukemia drug is safer than Imbruvica
Jan. 25, 2021
Woodcock steps in as acting FDA chief with crucial vaccine decisions ahead
Jan. 21, 2021
Pfizer, BioNTech say vaccine effective against fast-spreading UK coronavirus variant
Jan. 20, 2021
Cancer-focused biotech turns its tools to building a 2nd-generation coronavirus vaccine
Jan. 19, 2021
Former FDA chief Kessler tapped as top Biden adviser for COVID-19 response
Jan. 15, 2021
5 questions facing the FDA in 2021
Jan. 14, 2021
JPM21: Vaccines soar, antibodies struggle as COVID-19 drugs become a business
Jan. 12, 2021
JPM21: Biogen faces make-or-break year, Vertex mulls deals and Sarepta pitches a silver lining
Jan. 11, 2021
Celgene's cell therapy spinout nets $292M from blank-check merger
Jan. 8, 2021
Sarepta gene therapy misses goal in key muscular dystrophy study
Jan. 7, 2021
Pfizer beats Sarepta to start of first late-stage Duchenne gene therapy trial
Jan. 7, 2021
Leading $105M biotech funding, Bayer deepens cell therapy investment
Jan. 6, 2021
5 FDA approval decisions to watch in the 1st quarter
Jan. 5, 2021
AbbVie, Biogen lead pharma in new year's drug price hikes
Jan. 4, 2021
Merck signs $356M deal to supply US with experimental coronavirus drug
Dec. 23, 2020
With biosimilars looming, Roche makes case for new biologic eye drug
Dec. 21, 2020
A play-by-play of the FDA meeting on Moderna's coronavirus vaccine
Dec. 17, 2020
With trial plans, Novo wagers its diabetes drug can help treat Alzheimer's
Dec. 16, 2020
Lilly pays $880M for Prevail, pushing further into genetic medicine
Dec. 15, 2020
In historic decision, FDA clears coronavirus vaccine from Pfizer, BioNTech
Dec. 11, 2020
Lilly reports strong results for next-generation diabetes drug
Dec. 9, 2020
A play-by-play of the historic FDA meeting on Pfizer and BioNTech's coronavirus vaccine
Dec. 9, 2020
Researchers of the Year: The RECOVERY team
Dec. 9, 2020
In multiple myeloma, cell therapies lead but antibody drugs could follow fast
Dec. 8, 2020
J&J study finds multiple myeloma cell therapy to be strongly effective
Dec. 5, 2020
UK drug regulator is first to clear Pfizer, BioNTech's coronavirus vaccine
Dec. 2, 2020
CDC panel recommends giving first coronavirus vaccines to healthcare workers, nursing home residents
Dec. 1, 2020
Amgen cuts Cytokinetics loose after heart drug disappointment
Nov. 23, 2020
Trump administration pushes last-ditch plans to lower drug prices
Nov. 20, 2020
WHO recommends against Gilead's Veklury, in break with US guidelines
Nov. 20, 2020
FDA delays decision on Bristol Myers cell therapy, putting Celgene deal payouts in jeopardy
Nov. 17, 2020
Moderna's vaccine can last for weeks in a refrigerator, expanding an edge on rivals
Nov. 16, 2020
UCB strikes 2 gene therapy deals to build its pipeline
Nov. 12, 2020
Pfizer, BioNTech's strong results give lift to other coronavirus vaccines
Nov. 11, 2020
Coronavirus vaccine from Pfizer, BioNTech prevents COVID-19, early results show
Nov. 9, 2020
FDA advisers vote against Biogen's Alzheimer's drug, leaving its future in doubt
Nov. 6, 2020
FDA gene therapy holdups suggest closer scrutiny by agency
Nov. 5, 2020
Who would get Regeneron's COVID-19 antibody treatment?
Nov. 5, 2020
In 2020 election, an uncertain fate for drug price controls
Nov. 3, 2020
Revamp pays off for Kiadis with $358M Sanofi buyout
Nov. 2, 2020
Mirati cancer drug results spark hopes of outperforming Amgen's
Oct. 26, 2020
5 takeaways from the FDA's closely watched coronavirus vaccine meeting
Oct. 24, 2020
Facing vaccine doubts, US grapples with building confidence in coronavirus shots
Oct. 22, 2020
CRISPR Therapeutics reports remissions, one death in cancer cell therapy study
Oct. 21, 2020
5 questions ahead of this week's FDA meeting on coronavirus vaccines
Oct. 16, 2020
FDA puts Voyager study on hold in latest gene therapy speed bump
Oct. 13, 2020
Moderna says it won't enforce coronavirus vaccine patents during pandemic
Oct. 8, 2020
Pfizer and Sangamo, after rival's setback, kick off late-stage gene therapy trial
Oct. 7, 2020
FDA releases coronavirus vaccine guidelines that White House resisted
Oct. 6, 2020
Vir, GSK keep pace with rivals as COVID-19 antibody drugs grab spotlight
Oct. 6, 2020
From no drugs to 3: Patients with spinal muscular atrophy now face hard choices
Oct. 5, 2020
Solid gets all-clear from FDA to restart gene therapy trial
Oct. 1, 2020
Ironwood lays off one-third of staff after heartburn drug falls short in study
Sept. 29, 2020
FDA delays testing of Inovio's coronavirus vaccine
Sept. 28, 2020
Trump forges ahead with drug import plan, but impact in doubt
Sept. 25, 2020
Gene therapy company Taysha completes sprint from first funding to IPO
Sept. 24, 2020
AC Immune drug fails in blow to another Alzheimer's hypothesis
Sept. 23, 2020
FDA decision on Bristol Myers cell therapy could come down to the wire
Sept. 22, 2020
Seattle Genetics stays step ahead of rivals with bladder cancer data
Sept. 18, 2020
What to watch as the first late-stage coronavirus vaccine trials near potential readouts
Sept. 17, 2020
Arrowhead shares soar on liver disease data from four patients
Sept. 16, 2020
Novavax boosts coronavirus vaccine manufacturing capacity as key trial nears
Sept. 15, 2020
Trump releases long-awaited drug price order, but effects are likely far off
Sept. 14, 2020
Merck takes aim at Pfizer with pneumonia vaccine data
Sept. 9, 2020
Merck details cough drug data, raising questions about its potential
Sept. 8, 2020
Researchers publish first data on coronavirus vaccine approved by Russia
Sept. 4, 2020
Healthcare workers likely to be first in line for coronavirus vaccination
Sept. 1, 2020
Sanofi ends research of arthritis drug as coronavirus treatment
Sept. 1, 2020
Vir, GSK push coronavirus antibody drug straight into mid-stage tests
Aug. 31, 2020
CanSino said to seek early authorization of coronavirus vaccine
Aug. 28, 2020
Moderna's vaccine may have an edge when immunization programs roll out
Aug. 26, 2020
Moderna says its coronavirus vaccine sparks immune response in older people
Aug. 26, 2020
Sarepta, after two dramatic approvals, gets an FDA review for next Duchenne drug
Aug. 25, 2020
Moderna joins other vaccine leaders in European supply talks
Aug. 24, 2020
Coronavirus vaccine Pfizer, BioNTech chose for late-stage testing appears safer than first
Aug. 20, 2020
Momenta shift to new drugs pays off with $6.5B buyout by J&J
Aug. 19, 2020
Gilead expands Tango alliance, continuing a busy year of cancer deals
Aug. 18, 2020
Roche wins FDA approval for first self-administered biologic for rare eye disease
Aug. 17, 2020
AstraZeneca signals it won't wait for US data to seek clearance of coronavirus vaccine
July 30, 2020
Trump invites high-stakes showdown with big pharma as election looms
July 28, 2020
Moderna, pacing a global vaccine race, loses a key patent fight
July 24, 2020
Coronavirus vaccines speed ahead, but experts fear not everyone will take them
July 23, 2020
Pfizer and BioNTech coronavirus vaccine gets boost from German data
July 20, 2020
Side effects don't stop FDA panel from backing GSK blood cancer drug
July 15, 2020
Preventive studies for Eisai, Biogen Alzheimer's drug could add years to amyloid debate
July 14, 2020
Spark, chasing BioMarin, plans 2021 start for key hemophilia gene therapy study
July 13, 2020
FDA documents reveal doubts about GSK blood cancer drug
July 10, 2020
5 FDA approval decisions to watch in the 3rd quarter
July 8, 2020
US buys up early supply of Regeneron's COVID-19 antibody cocktail
July 7, 2020
Regeneron advances COVID-19 antibody cocktail into late-stage trials
July 6, 2020
Federal coronavirus contracts dodge pricing oversight, advocacy group says
July 1, 2020
Without data, Inovio says study shows positive results for coronavirus vaccine
June 30, 2020
Former BARDA director claims HHS leaders tried to 'thwart' him in new role
June 26, 2020
Price for Gilead's COVID-19 drug should shrink if cheap steroid widely used, ICER says
June 24, 2020
By $4M, La Jolla outbids Melinta for struggling Tetraphase
June 24, 2020
Gilead, in latest cancer bet, puts $275M into immunotherapy startup Pionyr
June 23, 2020
Vaccines can end the coronavirus pandemic. Will every country get them?
June 23, 2020
NIH ends key COVID-19 studies of hydroxychloroquine
June 22, 2020
UniQure gets out the gate first in race for Huntington's gene therapy
June 19, 2020
With new proposal, Trump administration tries to encourage 'value-based' drug deals
June 18, 2020
Cheap steroid lowers risk of death in hospitalized COVID-19 patients, U.K. study finds
June 16, 2020
CureVac gets German backing for coronavirus vaccine, but says it's independent
June 15, 2020
AstraZeneca spinout wins first FDA approval 2 years after launch
June 12, 2020
Pressure on generic drugmakers increases with new price fixing lawsuit
June 10, 2020
Drug regulators in agreement on coronavirus vaccine trials, FDA official says
June 9, 2020
The first coronavirus vaccines have arrived. Here's where the rest stand.
June 9, 2020
China's Innovent buys rights to Roche cancer technology
June 9, 2020
Alnylam details data for kidney disease drug under FDA review
June 8, 2020
AstraZeneca reaches deals with health charities to supply coronavirus vaccine worldwide
June 4, 2020
Hydroxychloroquine offers no COVID-19 protection after exposure, study shows
June 3, 2020
COVID-19 studies of malaria, blood pressure pills come under scrutiny
June 3, 2020
Bristol Myers follows Zeposia launch with positive data from key study
June 2, 2020
Regeneron expands Intellia gene editing deal as its post-Sanofi future emerges
June 1, 2020
AstraZeneca bid to expand lung cancer drug's use boosted by trial data
May 28, 2020
Novartis teams with Mass. Eye & Ear to join coronavirus vaccine chase
May 28, 2020
With $11B stock sale, Sanofi loosens ties with Regeneron
May 26, 2020
Intercept shares fall as FDA again delays closely watched NASH drug
May 22, 2020
Bangladesh pharma claims to be first to launch generic remdesivir
May 21, 2020
More questions than answers as Moderna's coronavirus vaccine speeds ahead
May 19, 2020
Ousted BARDA director: Hydroxychloroquine push distracted government scientists
May 14, 2020
J&J myeloma data heat up cell therapy battle
May 13, 2020
Activist investor pushes Alexion to sell after Portola deal
May 12, 2020
Dyno spins out of Harvard's laboratories with an aim to make gene therapy better
May 11, 2020
Novartis wins approval for niche lung cancer drug
May 7, 2020
After donation to the U.S., Gilead outlines plans to distribute COVID-19 drug worldwide
May 6, 2020
Pfizer, BioNTech launch U.S. trial of coronavirus vaccine
May 5, 2020
A coronavirus vaccine may arrive next year. 'Herd immunity' will take longer.
May 4, 2020
Texas university spins out Taysha, a gene therapy startup with 15 programs
April 29, 2020
Pfizer resumes trial recruitment suspended by coronavirus
April 28, 2020
Repurposed arthritis drug disappoints in closely watched COVID-19 trial
April 27, 2020
Malaria drug's potential against coronavirus dims as data mounts
April 22, 2020
Trial data help small biotech ready its anti-itch drug for approval
April 21, 2020
Positive data keep Bristol Myers and Exelixis in the kidney cancer race
April 20, 2020
Vir reminds biopharma its original aim is hepatitis B
April 16, 2020
J&J cuts sales forecast by $7B as coronavirus impact hits
April 14, 2020
AstraZeneca and Merck drug wins approval for rare cancer after failing elsewhere
April 13, 2020
Eye drug side effects are real, Novartis confirms in new warning
April 9, 2020
Myokardia at inflection point as heart drug readout nears
April 9, 2020
FDA delays decision on Roche spinal muscular atrophy drug
April 7, 2020
GSK bets $250M on Vir's antibody approach to treating coronavirus
April 6, 2020
Contamination concerns spur FDA call for nationwide withdrawal of heartburn drug
April 1, 2020
Under pressure, FDA touts speedy coronavirus drug development
April 1, 2020
Drugmakers await reckoning as doctors, patients make tough choices during pandemic
April 1, 2020
With latest FDA submission, Bristol Myers keeps pace with Celgene milestones
March 31, 2020
Merck's search for growth outside Keytruda may not end in heart disease
March 30, 2020
Sanofi adds mRNA to coronavirus vaccine push
March 27, 2020
Bristol Myers investors breathe easier as multiple sclerosis drug approved by FDA
March 26, 2020
In rare move, Gilead gives up 'orphan' status for experimental coronavirus drug
March 25, 2020
Leukemia drug from Roche, AbbVie extends survival, study finds
March 23, 2020
Remdesivir, chloroquine move to forefront as White House tries to speed coronavirus response
March 19, 2020
No White House offer for coronavirus vaccine access, CureVac says
March 17, 2020
Big pharma shied away from gene therapy for years. Academia picked up the slack
March 17, 2020
Regeneron and Sanofi speed Kevzara into coronavirus trials
March 16, 2020
New sickle cell drugs priced too high, ICER says
March 13, 2020
AstraZeneca and Merck's string of Lynparza successes ends in ovarian cancer
March 12, 2020
Coronavirus spread prompts FDA to postpone nearly all overseas inspections
March 10, 2020
Gates, Wellcome hatch $125M plan to speed coronavirus treatments
March 10, 2020
FDA, FTC put drugmakers on notice about tactics to block biosimilars
March 9, 2020
AstraZeneca immunotherapy combination falls short in bladder cancer trial
March 6, 2020
Federal prosecutors make another claim against Mallinckrodt over Acthar prices
March 4, 2020
New estimate puts cost to develop a new drug at $1B, adding to long-running debate
March 3, 2020
Sangamo sees vindication in Biogen gene-editing deal
Feb. 28, 2020
Takeda's small celiac disease bet turns into acquisition
Feb. 26, 2020
Mallinckrodt offers $1.6B in deal to settle opioid claims
Feb. 25, 2020
In a nod toward pharma, ICER makes deal to access real-world evidence
Feb. 24, 2020
Coronavirus weighs on AstraZeneca's China expansion
Feb. 14, 2020
Merck builds case for Keytruda use in breast cancer
Feb. 12, 2020
Exelixis prostate cancer data could help stave off competitive threats
Feb. 11, 2020
In Alzheimer's, a plan to treat patients earlier doesn't work out for Lilly, Roche
Feb. 10, 2020
Nestlé boosts investment as Aimmune preps launch of peanut allergy drug
Feb. 5, 2020
January price increases confirm slowing drug inflation
Feb. 4, 2020
US cancels trial after finding vaccine doesn't prevent HIV
Feb. 3, 2020
FDA approves Aimmune drug as first treatment for peanut allergy
Jan. 31, 2020
Amgen, Pfizer biosimilar sales pressure top drugs
Jan. 31, 2020
Preventive Alzheimer's trial data due within weeks, Lilly says
Jan. 30, 2020
Decibel CEO steps down as company pares workforce
Jan. 29, 2020
Pfizer lays out gene therapy aspirations
Jan. 28, 2020
To close merger, AbbVie and Allergan sell digestive drug to AstraZeneca
Jan. 27, 2020
FDA decision nears on Aimmune's contested peanut allergy drug
Jan. 24, 2020
Roche strengthens case for SMA drug with new study data
Jan. 23, 2020
Safety risks highlighted in FDA letter on Sarepta's Vyondys
Jan. 22, 2020
BeiGene cancer drug data sets up China duel with Merck
Jan. 21, 2020
Lilly seeking out more 'Dermira-like' deals: report
Jan. 17, 2020
Civica advances drug supply strategy with Thermo Fisher deal
Jan. 16, 2020
Astellas swoops in for Adaptimmune deal a day after positive data
Jan. 14, 2020
Biogen finds $75M home for Pfizer Alzheimer's drug
Jan. 13, 2020
Ultragenyx boosted by trial data for 2nd gene therapy
Jan. 10, 2020
5 trends to watch at the FDA in 2020
Jan. 9, 2020
Solid cuts one-third of staff, goes all in on delayed gene therapy
Jan. 9, 2020
AbbVie to house Allergan Botox business in separate unit
Jan. 8, 2020
Merck's Keytruda falls short of rivals in 1 lung cancer type
Jan. 7, 2020
Merck adds to lung cancer wall with Otsuka deal
Jan. 6, 2020
Wave's Huntington's drug shows effect but falls short of mark set by Roche and Ionis
Jan. 2, 2020
AstraZeneca and Merck's Lynparza cleared by FDA for pancreatic cancer
Dec. 30, 2019
Roche hands $1B to Sarepta in major return to gene therapy deals
Dec. 23, 2019
Daiichi, AstraZeneca breast cancer drug joins bumper crop of early FDA approvals
Dec. 20, 2019
AstraZeneca lupus drug shows potential, but it may not be enough for FDA
Dec. 19, 2019
Muscle data doesn't help Solid build faith in its gene therapy
Dec. 18, 2019
BeiGene's Brukinsa bet falls short against Imbruvica
Dec. 16, 2019
Wave cancels its Exondys competitor and heads back to the lab in muscular dystrophy
Dec. 16, 2019
In stunning twist, FDA approves Sarepta's Duchenne drug it rejected
Dec. 12, 2019
House passes drug pricing bill that pharma warned would bring 'nuclear winter'
Dec. 12, 2019
Value-based pricing for gene therapy? Maybe not ready for hemophilia
Dec. 11, 2019
UniQure, Pfizer updates hint at gene therapy potential in hemophilia B
Dec. 10, 2019
Leukemia rivals try to stay ahead as Merck, Lilly chase
Dec. 10, 2019
As CAR-T presses ahead in multiple myeloma, alternative approaches gain supporters
Dec. 9, 2019
Disruptor of the Year: The Federal Trade Commission
Dec. 9, 2019
Pharma of the Year: AstraZeneca
Dec. 9, 2019
We're not for sale, Alexion executives declare
Dec. 6, 2019
Cancer gene therapy backed by Blackstone gets trial win
Dec. 5, 2019
New approval for Roche's Tecentriq heats up lung cancer battle with Keytruda
Dec. 4, 2019
Will sky-high drug prices spur the US to use an obscure power over patents?
Dec. 4, 2019
Opioid makers subject of US grand jury probe
Nov. 27, 2019
Global Blood's sickle cell drug wins FDA approval, joining Novartis' Adakveo
Nov. 25, 2019
What Novartis needs to do to make Medicines Co. deal a success
Nov. 25, 2019
Calquence OK boosts AstraZeneca's challenge to Imbruvica
Nov. 22, 2019
FDA's rapid review pace nets an early approval for Alnylam's second drug
Nov. 20, 2019
France clears way for wide use of Vertex's Orkambi
Nov. 20, 2019
Alkermes follows up restructuring with Rodin acqusition
Nov. 18, 2019
Novartis sickle cell drug wins FDA approval
Nov. 15, 2019
BeiGene FDA cancer drug nod seen as breakthrough for Chinese biopharma
Nov. 15, 2019
Sarepta brings in more gene therapies with StrideBio deal
Nov. 14, 2019
ICER draws new gene therapy pricing framework
Nov. 13, 2019
Solid gene therapy trial halted again by FDA
Nov. 12, 2019
Roche's oral SMA drug scores in older patients
Nov. 11, 2019
Fibrogen, AstraZeneca confirm roxadustat's heart safety months after confusing first readout
Nov. 8, 2019
Sarepta tries softer approach to resolve FDA setback
Nov. 8, 2019
Celgene's last hurrah at ASH a defining moment for Bristol-Myers' buyout
Nov. 7, 2019
AstraZeneca's China ambitions grow with new R&D investments
Nov. 6, 2019
Third Neulasta biosimilar on its way as Sandoz wins long-delayed FDA approval
Nov. 5, 2019
Halozyme laying off 160 after pancreatic cancer trial comes up short
Nov. 4, 2019
Amgen's China ambitions become clear with BeiGene deal
Nov. 1, 2019
Sanofi pays $315 million to settle Lemtrada go-slow claims
Oct. 31, 2019
Novartis gene therapy ambitions dealt another blow by FDA hold on Zolgensma
Oct. 30, 2019
AstraZeneca joins Bristol-Myers' run at Merck in lung cancer
Oct. 28, 2019
Allergan pays $750M to rid itself of Namenda antitrust charges
Oct. 28, 2019
AstraZeneca blood cancer drug heading for showdown with AbbVie's
Oct. 24, 2019
Longtime Lilly diabetes chief Conterno to step down
Oct. 23, 2019
7 questions on Biogen's revival of a failed Alzheimer's drug
Oct. 22, 2019
Teva offers $23B of Suboxone to get out of opioid litigation
Oct. 21, 2019
Drug distributors, Teva settle in Ohio opioid case
Oct. 21, 2019
Merck's Ebola vaccine wins key European vote
Oct. 18, 2019
Give up board chairmanship? No thanks, US big pharma CEOs say
Oct. 16, 2019
Lilly shuttering UK neuroscience research site
Oct. 15, 2019
Pelosi drug plan would save $370B, but could reduce R&D, forecasters say
Oct. 14, 2019
On second thought, AbbVie's new arthritis drug not so costly, ICER says
Oct. 11, 2019
ProQR eye-disease data lend confidence that pivotal trial will succeed
Oct. 10, 2019
Feeling pressure in hemophilia, Novo signs gene editing deal with Bluebird
Oct. 9, 2019
Akcea inks deal with Pfizer, rebounding after leadership shuffle
Oct. 7, 2019
Sarepta, in shadow of FDA setback, marks gene therapy progress
Oct. 4, 2019
Amicus rare disease data build hope for approval
Oct. 2, 2019
FDA knocks back AstraZeneca's respiratory ambitions
Oct. 1, 2019
AstraZeneca, Merck strengthen lead in PARP drug class
Sept. 28, 2019
Medicines Co. gets cholesterol confirmation
Sept. 25, 2019
Clovis shares plunge after downgrade raises questions on path forward
Sept. 24, 2019
Amag fights activist investor's bid for board seats
Sept. 23, 2019
Is the future of diabetes treatment better drugs or better care?
Sept. 23, 2019
Novo gains approval for first oral diabetes drug of its kind
Sept. 20, 2019
The top drugs facing cuts under Pelosi's pricing plan
Sept. 20, 2019
House Democrats forge ahead with direct Medicare drug price negotiation
Sept. 19, 2019
Acceleron dealt pipeline setback
Sept. 17, 2019
5 questions ESMO cancer drug data might answer
Sept. 16, 2019
Another BACE dropped as Biogen and Eisai halt elenbecestat trials
Sept. 13, 2019
Adverum sinks on first gene therapy data for eye disease
Sept. 12, 2019
ICER dings Novo's new oral diabetes drug
Sept. 11, 2019
Medicare would negotiate prices for 250 drugs under House Democrats' plan
Sept. 10, 2019
Trial win could drive Acadia's Nuplazid to new use
Sept. 9, 2019
Roivant offloads biotech stakes in $3B alliance with Japanese pharma
Sept. 6, 2019
Novo Nordisk Foundation makes green grant to Danish-US university collaboration
Sept. 5, 2019
Ultragenyx gene therapy data disappoints investors
Sept. 5, 2019
Medicines Co.'s cholesterol drug looks good to take on PCSK9 rivals
Sept. 2, 2019
Novartis vies for multiple sclerosis dominance with Arzerra trial
Aug. 30, 2019
AstraZeneca gets lupus win but past failure could slow progress
Aug. 29, 2019
Amyloid's last hope? Prevention studies next big test for Alzheimer's research
Aug. 29, 2019
Immatics shows Celgene isn't done stocking cell therapy pipeline
Aug. 28, 2019
Gene editing companies oppose altering of embryos
Aug. 27, 2019
To patients, Sarepta repeats message on surprise rejection of Duchenne drug
Aug. 22, 2019
Sarepta now needs flawless progress for gene therapy
Aug. 20, 2019
Sarepta Duchenne drug rejected by FDA in surprise setback
Aug. 19, 2019
Pharming deal shows there's still life in struggling cancer drug class
Aug. 15, 2019
Regeneron gets cholesterol drug win where Praluent won't go
Aug. 14, 2019
Deciphera success sets up 2-horse race in gastrointestinal cancer
Aug. 13, 2019
AstraZeneca cancer drugs build as primary care shrinks
Aug. 12, 2019
Nektar battered over manufacturing issues and Bristol-Myers pullback
Aug. 9, 2019
Hospitalized gene therapy patient triggers Sarepta sell off
Aug. 8, 2019
Lilly shuffles executives overseeing oncology and M&A
Aug. 7, 2019
Teva finance chief resigns in midst of restructuring
Aug. 7, 2019
Amneal founders take reins as business struggles mount
Aug. 5, 2019
Sickle-cell setback triggers share slide at GlycoMimetics
Aug. 5, 2019
Takeda board lays out Shire integration goals
Aug. 2, 2019
Medicines Co. awaits its date with destiny
Aug. 1, 2019
White House backs importing drugs from abroad
July 31, 2019
How Mylan ended as a junior partner in its Pfizer deal
July 30, 2019
Mylan's tumble ends with Pfizer rescue
July 29, 2019
Senate advances drug pricing bill, setting up September vote
July 26, 2019
Roche highlights growth ahead of US biosimilar storm
July 25, 2019
Senate committee targets drug price increases with broad bill
July 23, 2019
Nonprofit US generics company secures supplier in Hikma
July 23, 2019
Opioid and price fixing legal liabilities mount for generic companies
July 22, 2019
Ultragenyx close to learning whether gene therapy gamble will pay off
July 19, 2019
MyoKardia cuts all ties to Sanofi
July 18, 2019
Merck urges caution on use of its newly approved antibacterial
July 17, 2019
Advocacy group pledges six-figure ad buy to support Trump drug price plan
July 17, 2019
Xarelto falls into the donut hole
July 16, 2019
AbbVie bets on early immuno-oncology asset
July 15, 2019
Amgen and Novartis halt Alzheimer's studies as faith in amyloid hypothesis dims
July 12, 2019
Billion-dollar settlement gets Reckitt out of federal opioid probes
July 11, 2019
In win for pharma, Trump TV drug price rule struck down
July 9, 2019
Roche acknowledges the obvious, extends Spark buyout deadline
July 8, 2019
Array pushed Pfizer for a higher price to get deal done
July 1, 2019
Pfizer muscular dystrophy gene therapy stumbles on safety
June 28, 2019
Zogenix boosted on FDA about-face for seizure drug application
June 27, 2019
AstraZeneca gets immuno-oncology win in a disease that Merck doesn't rule
June 27, 2019
AbbVie deal for Allergan not about the taxes, thanks to 2017 law
June 26, 2019
Novartis fights off generics courtroom challenge
June 25, 2019
Bristol-Myers price for Celgene now includes Otezla sell-off
June 24, 2019
Beating Keytruda a big task, Exelixis and Roche find
June 21, 2019
Sanofi to cut 466 workers in Europe as it seeks to refocus R&D
June 20, 2019
Pfizer goes big on targeted cancer therapies with $11.4B Array buy
June 17, 2019
Upadacitinib a plus for AbbVie in rheumatoid arthritis, doc survey says
June 14, 2019
Bluebird sets $1.8M price tag for blood-disease gene therapy
June 14, 2019
Savara lung disease trial misses, but execs vow to press on
June 13, 2019
FTC demands could mean months-long delay for Roche-Spark deal
June 12, 2019
Novo Nordisk goes for broke on semaglutide heart data
June 11, 2019
Trulicity heart data falls short for Lilly investors
June 10, 2019
Amicus widens UPenn gene therapy collaboration
May 29, 2019
BioMarin readies hemophilia gene therapy for FDA submission
May 28, 2019
Pay-for-delay deals disappearing, FTC says
May 24, 2019
Could Novartis' gene therapy have more than one price?
May 23, 2019
5 novel immuno-oncology targets to know before ASCO
May 22, 2019
No news is bad news for Tocagen
May 22, 2019
Array gets a win in colorectal cancer
May 21, 2019
Long-term heart data reassures for Medicines Co.
May 20, 2019
Medicare decides against tighter management of HIV drugs
May 17, 2019
Breast cancer survival data buoys Macrogenics and Puma
May 16, 2019
Cost-effectiveness agency clears Biogen's Spinraza for UK patients
May 15, 2019
Solid's gene therapy stumble makes Sarepta's lead clearer
May 14, 2019
Generics price-fixing lawsuit focuses on Teva's role as catalyst
May 13, 2019
Fibrogen confuses as it tries to explain blood-boosting drug data
May 10, 2019
Biopharma happily takes the tax cuts, but the jobs are harder to find
May 9, 2019
AstraZeneca's share dilution gamble on Daiichi drug pays off
May 8, 2019
Roche risdiplam data heats up SMA rivalry with Novartis
May 7, 2019
Novartis makes final Zolgensma pitch before FDA decision
May 6, 2019
Approval of $225,000-a-year tafamidis comes early for Pfizer
May 6, 2019
Rebate ban not a magic balm, federal budget forecasters say
May 3, 2019
Cost cuts to the rescue for Teva, so far
May 2, 2019
Generic Advair hits GSK revenues hard
May 1, 2019
Pfizer prospects for tafamidis market
April 30, 2019
Alexion, AstraZeneca secure backing of EMA panel for key drugs
April 29, 2019
Roche's takeout of Spark not working like a Swiss watch
April 26, 2019
Don't worry about Humira biosimilars, the pipeline will deliver, AbbVie says
April 25, 2019
Medicare proposes raising CAR-T pay, but reimbursement solution years away
April 24, 2019
Competition and donut hole discount takes toll on Xarelto sales
April 23, 2019
Safety setback for Pfizer, Lilly pain drug should have Regeneron and Teva feeling nervous
April 22, 2019
$300M loan boosts launch of TherapeuticsMD hot flash pill
April 18, 2019
Sarepta may have seen off another rival in Wave
April 17, 2019
Its ambitions restrained, Amgen sets modest Evenity price
April 16, 2019
Kidney data may give J&J diabetes drug an edge
April 15, 2019
Gilead and Novo Nordisk pair up to take on NASH
April 12, 2019
Intercept sputters as it reveals full Ocaliva NASH data to doctors
April 11, 2019
Indivior draws criminal indictment for opioid marketing practices
April 10, 2019
Pharmacy's 'middlemen' counter pharma's campaign to shift the price blame
April 9, 2019
Audentes lays down marker in muscular dystrophy
April 8, 2019
Copay assistance snares 3 drug companies in Medicare kickback charges
April 5, 2019
What to look for after Zolgensma's launch
April 4, 2019
Roche must ask Spark shareholders once again to sell
April 3, 2019

Home
- Pharma
- Biotech
- FDA
- Clinical Trials
- Deals
- Drug Pricing
- Gene Therapy
Deep Dive
Library
Events

Get BioPharma Dive in your inbox

The free newsletter covering the top industry headlines

Select Newsletter: Daily Dive
Topics covered: Pharma, biotech, FDA, gene therapy, clinical trials, drug pricing and much more.
M-F view sample
Select Newsletter: Commercialization Weekly Every Wednesday view sample
Select Newsletter: Gene Therapy Weekly Every Thursday view sample
Select user consent: By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy. You can unsubscribe at anytime.